Subsequently, expert consensus panels of the American Association of Kidney Patients and of the National Kidney Foundation have recommended intravenous L-Carnitine for treatment of erythropoietin-resistant anemia, dialysis hypotension, cardiomiophaty and muscle weakness [80]. This evidence concerns the gene EPO and anemia (phenotype).